

Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1-15 (Cancelled)

16. (Currently amended) A method for treating ~~or preventing~~ Japanese cedar pollen allergy in a subject in need thereof, the method comprising:

- (a) identifying an HLA class II molecule expressed by the subject;
- (b) selecting an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Cry j 2, wherein the antigenic peptide binds to HLA class II molecule and wherein:

- (1) when the HLA class II molecule identified in step (a) is DQA1*0102-DQB1*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO: 1, 5, 7, 9, 10, 21, 23, and 142;

- (2) when the HLA class II molecule identified in step (a) is DPA1*0101-DPB1*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 2, 8, and 15;

- (3) when the HLA class II molecule identified in step (a) is DPA1*0101-DPB1*0201, the antigenic peptide is SEQ ID NO: 17;

- (4) when the HLA class II molecule identified in step (a) is DPA1*0202-DPB1*0501, the antigenic peptide is SEQ ID NO: 22;

- (5) when the HLA class II molecule identified in step (a) is DRB5*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 3, 4, 14, and 19;

- (6) when the HLA class II molecule identified in step (a) is DRB1*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO: 6, 7, 12, 16, and 20;

- (7) when the HLA class II molecule identified in step (a) is DRB4*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 7, 12, and 18; and

(8) when the HLA class II molecule identified in step (a) is DRB1*1501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 13 and 19; and
(c) administering the selected antigenic peptide to the subject.

17. (Previously presented) A customized pharmaceutical composition for treating a subject suffering from a Japanese cedar pollen allergy, the composition comprising:

(a) an effective amount of an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Cry j 2, wherein the antigenic peptide binds to an HLA class II molecule expressed by the subject and wherein:

(1) when the subject expresses the HLA class II molecule DQA1*0102-DQB1*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO: 1, 5, 7, 9, 10, 21, 23, and 142;

(2) when the subject expresses the HLA class II molecule DPA1*0101-DPB1*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 2, 8, and 15;

(3) when the subject expresses the HLA class II molecule DPA1*0101-DPB1*0201, the antigenic peptide is SEQ ID NO: 17;

(4) when the subject expresses the HLA class II molecule DPA1*0202-DPB1*0501, the antigenic peptide is SEQ ID NO: 22;

(5) when the subject expresses the HLA class II molecule DRB5*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 3, 4, 14, and 19;

(6) when subject expresses the HLA class II molecule DRB1*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO: 6, 7, 12, 16, and 20;

(7) when the subject expresses the HLA class II molecule DRB4*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 7, 12, and 18; and

(8) when the subject expresses the HLA class II molecule DRB1*1501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 13 and 19; and

Applicant : Toshio Sone et al.
Serial No. : 09/308,027
Filed : August 16, 1999
Page : 4 of 6

Attorney's Docket No.: 14883-031001 / M1-808PCT-
US

(b) a pharmaceutically acceptable diluent or carrier.